0 32

Cited 0 times in

Coronary Stenting (Cordis) Without Anticoagulation

DC FieldValueLanguage
dc.contributor.author장양수-
dc.date.accessioned2020-07-03T17:17:28Z-
dc.date.available2020-07-03T17:17:28Z-
dc.date.issued1997-
dc.identifier.issn0002-9149-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/177412-
dc.description.abstractWe evaluated the effect of antithrombotic regimens on subacute thrombosis and short-term clinical courses after successful implantation of the Cordis coronary stent, which is a flexible, balloon expandable, radiopaque tantalum stent. Two hundred seventy-five consecutive patients with 290 lesions were treated with 356 Cordis stent implantations. According to poststent antithrombotic regimen, patients were divided into 3 groups; 165 patients with 175 lesions received aspirin 200 mg/day, ticlopidine 500 mg/day, and warfarin for 1 month (group 1), 66 patients with 69 lesions received aspirin and ticlopidine (group 2), and 44 patients with 46 lesions received aspirin alone (group 3) after successful Cordis stenting. The overall procedural success rates were 97.7% in group 1, 98.6% in group 2, and 100% in group 3. More than 65% of the patients were eligible for elective stenting. The overall rate of stent thrombosis was 1.8%: 1.2% in patients assigned to the treatment with aspirin, ticlopidine, and warfarin; 0% in patients with aspirin and ticlopidine; and 6.8% in patients assigned to the treatment with aspirin alone. In conclusion, the Cordis coronary stent is an effective endovascular stent in various clinical indications including unstable angina and acute myocardial infarction. Antiplatelet therapy using aspirin and ticlopidine after successful Cordis coronary stenting is a promising alternative to anticoagulation therapy to overcome the drawbacks of stenting. However, poststent antithrombotic therapy with aspirin alone is associated with a significant rate of stent thrombosis.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherExcerpta Medica-
dc.relation.isPartOfAMERICAN JOURNAL OF CARDIOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAnticoagulants/therapeutic use*-
dc.subject.MESHAspirin/therapeutic use-
dc.subject.MESHCoronary Angiography-
dc.subject.MESHCoronary Disease/therapy*-
dc.subject.MESHCoronary Thrombosis/diagnostic imaging-
dc.subject.MESHCoronary Thrombosis/prevention & control*-
dc.subject.MESHEvaluation Studies as Topic-
dc.subject.MESHFibrinolytic Agents/therapeutic use*-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPlatelet Aggregation Inhibitors/therapeutic use-
dc.subject.MESHStents*-
dc.subject.MESHTiclopidine/therapeutic use-
dc.subject.MESHTime Factors-
dc.subject.MESHWarfarin/therapeutic use-
dc.titleCoronary Stenting (Cordis) Without Anticoagulation-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSeong-Wook Park-
dc.contributor.googleauthorSeung-Jung Park-
dc.contributor.googleauthorMyeong-Ki Hong-
dc.contributor.googleauthorJae-Joong Kim-
dc.contributor.googleauthorSeung-Yun Cho-
dc.contributor.googleauthorYang-Soo Jang-
dc.contributor.googleauthorKwon-Bae Kim-
dc.contributor.googleauthorKee-Sik Kim-
dc.contributor.googleauthorDong-Joo Oh-
dc.contributor.googleauthorByung-Hee Oh-
dc.contributor.googleauthorJung-Chaee Kang-
dc.identifier.doi10.1016/s0002-9149(97)00017-9-
dc.contributor.localIdA03448-
dc.relation.journalcodeJ00071-
dc.identifier.eissn1879-1913 -
dc.identifier.pmid9104903-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0002914997000179?via%3Dihub-
dc.contributor.alternativeNameJang, Yang Soo-
dc.contributor.affiliatedAuthor장양수-
dc.citation.volume79-
dc.citation.number7-
dc.citation.startPage901-
dc.citation.endPage904-
dc.identifier.bibliographicCitationAMERICAN JOURNAL OF CARDIOLOGY, Vol.79(7) : 901-904, 1997-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.